FDA Approves Merck's KEYTRUDA Combo for Aggressive Breast Cancer
Merck (MRK) announced on June 25 that the FDA approved both KEYTRUDA and KEYTRUDA QLEX in combination with Gilead's (GILD) Trodelvy as a first-line treatment for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer. This combination could become the standard of care.
Merck & Co., Inc. (NYSE:MRK) announced on June 25 that the U.S. Food and Drug Administration (FDA) approved both KEYTRUDA and KEYTRUDA QLEX each in combination with Gilead's Trodelvy as a first-line treatment for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
The Product
KEYTRUDA is a PD-1 inhibitor, while Trodelvy is a Trop-2-directed antibody-drug conjugate. The combination enhances immune response against cancer cells while targeting the Trop-2 protein highly expressed in TNBC tumors.
Pricing and Availability
Merck has not disclosed pricing details yet, but the treatment is expected to be available immediately following approval. KEYTRUDA QLEX is a subcutaneous formulation administered in 3-5 minutes, reducing treatment time.
Competition
This combination competes with other therapies such as Roche's Tecentriq and AstraZeneca's Imfinzi. However, this is the first approval of a PD-1 inhibitor plus an antibody-drug conjugate in this setting.
Potential Impact on the Company
This approval could boost KEYTRUDA revenues (which reached $25 billion in 2025) and expand Trodelvy's use for Gilead. Both stocks may see positive movements, but the full impact will be reflected in quarterly sales data.
Frequently Asked Questions
Found this useful? Share it